Contact

Our portfolio

PacingCure

PacingCure is pioneering gene therapy solutions to cure heart conditions that results in pacing issues. The company focuses on developing biological pacemakers for patients who cannot use conventional electronic pacemaker devices. Their research explores various transgenes and delivery systems to modulate heart pacing. PacingCure is dedicated to advancing cardiac care through innovative gene therapy.

  • Institute: Amsterdam UMC
Industry: Cardiology, Gene Therapy, Therapeutics
  • Founding year: 2016
Visit website

Want to get in contact about PacingCure?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Nano Hybrids
Advancing nanotechnology with sustainable, solvent-free nanoparticle synthesis.
Pepper Therapeutics
Repurposing the obsolete diabetes drug phenformin into an affordable and widely available therapy for pancreatic cancer
ikHerstel
Speeding up post-surgical rehabilitation with a personalized e-health recovery platform.
InSteps
Digitizing stroke treatment development and planning with an in-silico stroke simulation platform.
Nano Hybrids
Advancing nanotechnology with sustainable, solvent-free nanoparticle synthesis.
Pepper Therapeutics
Repurposing the obsolete diabetes drug phenformin into an affordable and widely available therapy for pancreatic cancer
ikHerstel
Speeding up post-surgical rehabilitation with a personalized e-health recovery platform.
InSteps
Digitizing stroke treatment development and planning with an in-silico stroke simulation platform.
Explore full AAV portfolio
Contact